Malvern Instruments has established a new biopharmaceutical applications laboratory in the heart of San Diego’s biotechnology cluster in California, US, to enable customers and Malvern applications specialists to experience and use the company's specialist biophysical characterisation systems in a working environment.
The new lab has been developed in partnership with Sevion Therapeutics, a San Diego-based biopharmaceutical company that discovers, develops and acquires next-generation biologics. Sevion Therapeutics will host the laboratory for which Malvern will provide analytical instrumentation, training and continuing support.
'As evidenced by the work of our Bioscience Development Initiative team, Malvern is absolutely committed to providing cutting edge analytical instrumentation that meets the needs of the biopharmaceutical industry,' said Paul Davies, Global Business Manager at Malvern Instruments. 'We work closely with all parts of the pharmaceutical industry but the highly dynamic nature of biopharmaceutical development and the rapid pace of change make it imperative that we have a fully functioning applications laboratory in an environment where there is access to real-world protein formulations and where our instruments sit within the workflow of a commercial enterprise.'
Under the terms of the agreement, two Malvern microcalorimeters – the new MicroCal PEAQ-ITC and a MicroCal VP-Capillary DSC – plus a Viscotek TDAmax multi-detector size exclusion chromatography system, and a Zetasizer Nano ZSP for the measurement of size, electrophoretic mobility of proteins, zeta potential of nanoparticles and surfaces, are installed in the new lab.
Further protein characterisation technologies from Malvern’s portfolio will be installed in the future.